arrow
K

Keisho Chìn

Department of Gastroenterological Chemotherapy
H指数:41
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort

糖皮质激素在粒细胞集落刺激因子相关大血管血管炎中很少需要:日本癌症中心队列

2025-12-010
PRE
Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

早期较高的血浆瑞戈菲布浓度预示日本结直肠癌患者无进展生存期缩短

2025-11-040
OAAI
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

使用术前血管内皮生长因子抑制剂的既往用药对三氟尿idine/替吡拉塞联合贝伐珠单抗在转移性结直肠癌患者中安全性与有效性的影响

2025-07-210
PRE
Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial

局部晚期食管鳞状细胞癌患者新辅助化疗和手术后辅助S-1的II期试验:

2024-10-071
OAAI
Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial

诱导化疗后内镜分期以预测低位直肠癌完全新辅助治疗后的完全应答和生存:IMPACT试验的专项分析

2024-09-010
PRE
Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy

HER2阳性晚期胃癌中肿瘤内HER2异质性与循环肿瘤DNA的相关性:HER2和PD-1双靶向治疗(Ni-High) Ib期试验的子研究

2024-09-010
PRE
Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
2023-11-010
OA
APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/ capecitabine plus oxaliplatin combined with trastuzumab (Tmab) and nivolumab (N-mab)
2023-10-010
OA
Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study
2023-08-231
OAAI
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma

低HER2表达、不能手术、晚期或复发性胃/胃食管交界处腺癌的发病率、临床病理特征和临床预后

2023-08-018
OAAI
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors

单器官肺转移是接受FOLFIRI和血管内皮生长因子抑制剂治疗的转移性结直肠癌患者的有利预后因素

2023-07-061
OAAI
Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study

曲妥珠单抗Deruxtecan和Nivolumab作为HER2-Positive晚期胃癌三线或后线治疗的疗效和安全性: 单机构回顾性研究

2023-01-012
OAAI